Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 18/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 11/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8625458 | 0.98 | PTGS2 (0.67) | PTGS2PTGS1ABCB11ALDH1A1 | |
| Benzenesulfonamide SCHEMBL7641687 | 0.95 | PTGS2 (0.70) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL8637047 | 0.90 | PTGS2 (0.63) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL7928751 | 0.90 | PTGS2 (0.66) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL8165901 | 0.88 | PTGS2 (0.62) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL7926014 | 0.86 | PTGS2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL8525009 | 0.86 | PTGS2 (0.65) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL8688532 | 0.85 | PTGS2 (0.57) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL8692480 | 0.84 | PTGS2 (0.50) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL8635925 | 0.84 | PTGS2 (0.58) | PTGS2PTGS1ABCB11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1443967-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | Novartis AG (CH) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003039599-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | NOVARTIS AG (CH) | 2003-05-15 | — | — | WO | disclosed |